entertainment -WSS

entertainment

author：comprehensive 2025-10-01 13:59:20 - browse：6

a doctor wraps a smart watch around a patient's wrist — Adobe

As pharma companies wrestle with how and when to use wearables and other digital technologies to measure how their experimental drugs impact patients, clinical research giant Icon has acquired HumanFirst, which helps companies answer exactly those sorts of questions.

Founded in 2017, HumanFirst maintains a meticulously organized library of digital measurement tools, their underlying evidence, and information about how they have been used in clinical trials. Called Atlas, the platform is designed so that a trial sponsor can research what tools are available to measure things like physical activity or sleep for many commonly studied diseases. CEO Andy Coravos said that robust intelligence can help developers move more quickly and avoid mistakes that require costly changes to trial protocols.

Following the acquisition, HumanFirst will be another offering for Icon, which earned $8 billion last year running clinical trials for pharmaceutical companies and other related services. As of 2021, HumanFirst had raised $15 million in venture capital funding, and the decision to sell to Icon for an undisclosed amount comes as some big drug companies are reevaluating their approach to digital technologies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： How to save health care price transparency rules

leisure time

WSS

Ebola: Gilead Sciences antiviral shows promise as new treatment

UPS workers' union leader explains what's at stake as strike edges closer

Titanic submersible: What a 'catastrophic implosion' means and what officials found

What to know about a major upcoming Wegovy heart health study

How redistricting in 6 states could affect who controls Congress

Male and female sex labels in research insufficient, scientists say

focus

entertainment

leisure time

Medicare details structure of new drug price negotiation program

John Green on his newest strategy for fighting tuberculosis

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

How redistricting in 6 states could affect who controls Congress

State Dept. review finds Biden bears some blame for Afghanistan failures

Trump seeks lengthy delay of classified docs trial, citing upcoming election

Medical records are filled with copy

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Apple is now the first public company to be valued at $3 trillion

Pushing for an NIH office for post

explore

RaDonda Vaught links Vanderbilt hospital issues to patient death

UCLA team creates talking throat patch for voice disorders

UPS workers' union leader explains what's at stake as strike edges closer

Readout Newsletter: CAR

How many hemophilia patients actually want gene therapy?

How to save health care price transparency rules

focus

leisure time

hotspot

focus